Atrial Fibrillation

A 63-year-old Black woman walks into a clinic with palpitations and gets told she's anxious. Six months later she has a stroke. The autopsy of that story, repeated across the country, is what cardiologists now call the racial paradox of atrial fibrillation: by every large epidemiologic measurement we have, Black Americans develop A-Fib less often than white Americans, and yet Black patients with A-Fib are about twice as likely to have a stroke and twice as likely to die from it (Magnani et al., JAMA Cardiology 2016, PMID 27438320).

A-Fib is the most common sustained abnormal heart rhythm. The top chambers of the heart (atria) quiver instead of squeezing, blood pools, clots form, and those clots can travel to the brain. Treatment has two jobs: control the rhythm or rate, and prevent the stroke. The 2023 ACC/AHA/ACCP/HRS guideline (Joglar et al., Circulation 2024, PMID 38033089) is the current standard, and for the first time it dedicates a section to health inequities and barriers to A-Fib management. That section exists because the gap between what Black patients are owed and what they receive has been measured, repeatedly, for fifteen years.

• Palpitations, described as a fluttering, pounding, or galloping in the chest, sometimes only at night or after caffeine
• Shortness of breath, especially climbing stairs or lying flat
• Fatigue that is new, persistent, and not explained by sleep or workload
• Lightheadedness or near-fainting
• Chest discomfort or pressure
• A pulse that feels irregular when you press two fingers to your wrist or neck
• No symptoms at all. Paroxysmal A-Fib can be completely silent and is sometimes first discovered when a smartwatch flags it or after a stroke

There is no universal A-Fib screening recommendation for asymptomatic adults from the U.S. Preventive Services Task Force; the 2022 USPSTF statement concluded evidence was insufficient. The 2023 ACC/AHA/ACCP/HRS guideline (Joglar et al., Circulation 2024, PMID 38033089) recommends considering screening in adults 65 and older, particularly those with multiple risk factors. In practice that means a pulse check at every visit, a 12-lead ECG when palpitations are reported, and ambulatory monitoring (Holter, patch monitor, or implantable loop recorder) when symptoms are intermittent. Consumer wearables (Apple Watch, Fitbit, KardiaMobile) have FDA-cleared single-lead ECG features and can catch episodes a clinic ECG misses; a wearable alert should be taken to a clinician, not dismissed.

Treatment has two tracks that run in parallel. Stroke prevention is the first and the one that bends the mortality curve. For most patients with a CHA2DS2-VASc score of 2 or higher (1 or higher in some scenarios), the 2023 guideline recommends a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) over warfarin as first line, with warfarin reserved for mechanical heart valves and moderate-to-severe mitral stenosis. Given the documented prescribing disparity (Essien, JAMA Cardiology 2018), a Black patient with A-Fib should specifically ask why a DOAC is or is not being offered, and whether cost or a guideline reason is driving the choice. Patient assistance programs exist for every approved DOAC.

Rhythm and rate control is the second track. Rate control uses beta blockers (metoprolol, carvedilol) or calcium channel blockers (diltiazem, verapamil) to slow conduction at the AV node. Rhythm control uses antiarrhythmic drugs (flecainide, propafenone, amiodarone, dronedarone, sotalol) or catheter ablation. The 2023 guideline upgraded catheter ablation to a Class I recommendation as first-line therapy for symptomatic paroxysmal A-Fib in selected patients, a notable change from prior guidelines. Risk-factor modification (treating hypertension to target, weight loss if BMI is elevated, treating obstructive sleep apnea, reducing alcohol) is now formally part of treatment, not lifestyle advice tacked on at the end.